Peptide therapy, decoded.

200+ clinical monographs, interactive dosing calculators, and community reviews — all PubMed-referenced and free to access.

200+ Monographs·14 Clinical Tools·37 Languages·PubMed-Referenced·No Pharmacy Affiliations

Latest Research & Education

Article

Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis

Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant antifibrotic activity in pulmonary fibrosis models by functioning as a PAR-1 antagonist that disrupts the coagulation factor Xa-PAR-1 signaling axis. The peptide inhibited fibroblast invasion and migration with a favorable safety profile—no adverse effects at 0.5 mg/kg/day and only mild hepatomegaly at supratherapeutic doses.

Peptide Publicus Editorial··1 min read
Evidence-based
Guides

هل الببتيدات آمنة: ما تقوله الأبحاث السريرية

هل الببتيدات آمنة للاستخدام؟ نستعرض ما تقوله الأبحاث السريرية والتجارب المحكّمة حول سلامة الببتيدات العلاجية، مع الإشارة إلى تصنيفات الهيئات الصحية في المنطقة العربية مثل SFDA وMOHAP، والآثار الجانبية المُوثّقة علمياً.

Peptide Publicus Editorial··5 min read
Evidence-based
Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Peptide Publicus Editorial··2 min read
Evidence-based
Informational

ما هي الببتيدات وكيف تعمل في الجسم؟ دليل شامل

الببتيدات سلاسل قصيرة من الأحماض الأمينية تؤدي أدواراً حيوية في التمثيل الغذائي والمناعة وإصلاح الأنسجة. يشرح هذا الدليل بنيتها وآليات عملها وتطبيقاتها العلاجية المعتمدة في المنطقة العربية وفق لوائح الهيئة العامة للغذاء والدواء (SFDA) ووزارة الصحة الإماراتية (MOHAP).

Peptide Publicus Editorial··5 min read
Evidence-based

Real Experiences from Real UsersNEW

BPC-157
Worth it

Game-changer for my knee recovery

After 6 weeks of subcutaneous injections, the chronic tendon pain I'd had for 2 years was down to almost nothing. Combined with PT, the results were remarkable.

Verified user · 8 weeks

Semaglutide
Worth it

Steady weight loss, minimal sides

Lost 14 lbs over 3 months on the titration schedule. Nausea was real the first 2 weeks but manageable. Worth it for the appetite control alone.

Verified user · 12 weeks

CJC-1295 + Ipamorelin
Worth it

Best GH stack I've tried

Noticeably better sleep by week 2, improved recovery from training by week 4. Skin quality improved. No water retention like with GHRP-6.

Verified user · 16 weeks

200+

Monographs

14

Interactive Tools

37

Languages

100%

Independent

كن دائمًا في الصورة

تحديثات سريرية، أخبار الصناعة، ملخصات أبحاث جديدة، وإصدارات أدوات.

نحترم خصوصيتك. يمكنك إلغاء الاشتراك في أي وقت.